Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Boehringer Ingelheim Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted to regulate the importation, supply, and other aspects of therapeutic goods in Australia, was introduced to address the need for a comprehensive legislative framework that ensures the safety, quality, and efficacy of therapeutic goods. This Act was passed by the Parliament of Australia to provide a robust system for the regulation of therapeutic goods, aiming to protect public health by ensuring that only goods of acceptable quality are made available for use. In this instance, the Therapeutic Goods Administration (TGA) under the Department of Health issued a notice granting consent for the importation and supply of DULCOLAX bisacodyl 5 mg tablet blister packs that do not fully conform to certain specifications, reflecting the Act's objective to balance regulatory standards with practical considerations in the pharmaceutical market. The policy objective underpinning this consent is to facilitate access to necessary therapeutic goods while maintaining high standards of quality and safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, blood, tissues, and vaccines, across the Commonwealth of Australia. This Act regulates the importation, supply, and advertising of therapeutic goods to ensure they meet safety, quality, and efficacy standards. It applies to individuals, companies, and entities involved in the production, importation, supply, and advertising of therapeutic goods. The Act’s jurisdiction encompasses the entire Commonwealth, with specific sections extending to state and territory levels where applicable. The Act includes certain exclusions, such as goods primarily for personal use, and allows for exemptions or special provisions under specific conditions, including therapeutic goods for clinical trials or research. The application of the Act can be further defined and extended through subordinate instruments, such as regulations and orders, which provide detailed specifications and additional requirements for particular therapeutic goods or circumstances.

Key Provisions

The Therapeutic Goods Act 1989, as amended by section 14 and 14A, enables the delegate of the Secretary of the Department of Health to provide consent for the importation and supply of therapeutic goods that do not fully conform to specified standards. In this instance, the delegate granted consent (section 14) for Boehringer Ingelheim Pty Limited to import and supply DULCOLAX bisacodyl 5 mg tablet blister packs that do not meet the requirements of section 8 of the Therapeutic Goods Order No. 78 Standard for Tablets and Capsules (section 14A). This specific consent is related to the non-compliance with the related substances requirements of the British Pharmacopoeia monograph for Gastro-resistant Bisacodyl Tablets. The consent is effective from 19 November 2015 until 19 November 2017, providing a limited window for the supply of these non-compliant products. The Act imposes several obligations on the parties involved. Firstly, the product must adhere to the approved in-house specification 0001891-115R-03 for the content of related substances, as outlined in the conditions of the consent. This specification acts as a benchmark to ensure that the product maintains a certain level of quality and safety, despite not meeting the full pharmacopoeia standards. Additionally, the product must comply with all other applicable parts of the British Pharmacopoeia monograph for Gastro-Resistant Bisacodyl Tablets, as well as any other relevant standards. This ensures that while the product may not fully align with the specified monograph, it still meets the necessary safety and efficacy requirements. Failure to comply with the conditions outlined in the consent may result in legal consequences. Under the Therapeutic Goods Act 1989, breaches of the conditions can lead to enforcement actions, including fines and potential criminal charges. The specific penalties for breaches are not detailed in the provided notice, but they can include substantial fines and imprisonment, depending on the severity and intent of the breach. It is crucial for Boehringer Ingelheim Pty Limited to adhere strictly to the conditions of the consent to avoid these potential consequences. The delegate of the Secretary retains the right to revoke the consent if the conditions are not met, further emphasising the importance of compliance.